Study guide

1.3 USP <797> Categories 1, 2, and 3 CSP Classification

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

1.3 USP <797> Categories 1, 2, and 3 CSP Classification

Key Takeaways Explain This Topic AI

The 2023 revision of USP <797> replaced the 2008 risk levels (low, medium, high) with Categories 1, 2 and 3. The categories depend on where the CSP is made, how it is tested, and the BUD it receives.

Category 1 CSPs may be made in an unclassified Segregated Compounding Area (SCA) and are capped at 12 hours at controlled room temperature or 24 hours refrigerated.

Category 2 CSPs require a cleanroom suite (or a pharmaceutical isolator in an ISO Class 8 room). The longest Table 13 BUDs (45 days at room temperature, 60 refrigerated, 90 frozen) require terminal sterilization plus a passing sterility test.

Category 3 CSPs can reach 60/90/120 days (aseptic) or 90/120/180 days (terminally sterilized). They require sterility testing of every batch, stability-indicating data, sterile garb with no exposed skin, weekly sporicidal and surface sampling, monthly air sampling, and competency every 3 months.

Last updated: September 2026

1.3 USP <797> Categories 1, 2, and 3 CSP Classification

Note

Executive Summary: A defining advancement of the 2023 revision of USP General Chapter <797> was the complete replacement of the legacy 2008 risk-level paradigm ("low-, medium-, and high-risk compounding") with three objective operational categories: Category 1 , Category 2 , and Category 3 . This modern classification establishes Beyond-Use Dating (BUD) ceilings based directly upon verifiable engineering controls, starting component bioburden, analytical sterility testing, and personnel qualification rigor.

The Paradigm Shift: Why Legacy Risk Levels Were Replaced

Under the 2008 edition of USP <797>, compounding risk was stratified based on subjective operational complexity:

Low-risk level: ≤ 3 commercially manufactured sterile packages and ≤ 2 entries into any single container.

Medium-risk level: Multiple individual or small doses pooled, complex manipulations, or prolonged compounding duration (e.g., automated total parenteral nutrition [TPN] batching).

High-risk level: Utilizing non-sterile starting ingredients, non-sterile bulk chemical powders, or open-air exposure of sterile components.

This legacy taxonomy exhibited significant regulatory and microbiological flaws. It conflated facility engineering quality with compounding manipulation counts, failed to establish clear analytical thresholds for extended storage, and introduced substantial ambiguity regarding segregated compounding areas. The 2023 revision discarded this subjective framework in favor of three objective categories defined by the physical environment, component sterility, release testing, and monitoring frequency.

Category 1 Compounded Sterile Preparations

Category 1 CSPs are formulated to accommodate rapid clinical deployment in environments lacking a classified cleanroom suite, such as hospital satellite pharmacies, emergency department compounding rooms, outpatient oncology clinics, and ambulatory surgical centers.

Environmental & Engineering Specifications:

Primary Engineering Control (PEC): Must be compounded inside an ISO Class 5 PEC (such as a Laminar Airflow Workbench [LAFW], Class II Biological Safety Cabinet [BSC], or Compounding Aseptic Isolator [CAI]).

Secondary Engineering Control (SEC): May be located inside an unclassified Segregated Compounding Area (SCA) or within a certified cleanroom suite. The SCA must have a defined perimeter and must be dedicated to compounding. It must be located away from unsealed windows, doors to the outdoors, and traffic flow, and it cannot sit where restrooms, warehouses, or food preparation areas threaten air quality. Any hand-washing sink must be at least 1 meter from the PEC.

Starting Components: May utilize sterile commercial products or non-sterile bulk chemicals. If non-sterile components are used, the preparation must be sterilized (e.g., by sterilizing filtration or terminal sterilization). Whatever the starting components, a CSP compounded in an SCA stays within the Category 1 BUD limits.

Beyond-Use Dating (BUD) Ceilings for Category 1:

Controlled Room Temperature (20°C to 25°C): Maximum 12 hours .

Refrigerated Storage (2°C to 8°C): Maximum 24 hours .

Frozen Storage (-25°C to -10°C): Prohibited (Category 1 CSPs can never be frozen).

Category 2 Compounded Sterile Preparations

Category 2 represents standard cleanroom sterile compounding, comprising the vast majority of daily parenteral admixtures prepared in institutional health-system cleanrooms and centralized compounding pharmacies.

Environmental & Engineering Specifications:

Secondary Engineering Control (SEC): Must be prepared in a certified cleanroom suite consisting of:

An ISO Class 5 PEC.

Located inside an ISO Class 7 positive-pressure buffer room (or negative pressure for hazardous compounding under USP <800>).

Supported by an ante-room providing ISO Class 7 air (if opening into a negative-pressure buffer room) or ISO Class 8 air (if opening into a positive-pressure buffer room).

Isolator placement: A CAI or CACI is a restricted-access barrier system (RABS). If it is used for Category 2, it must sit inside a cleanroom suite with an ISO Class 7 or better buffer room and an ISO Class 8 or better anteroom. The 2008 exemption that let CAIs outside a cleanroom earn longer dating is gone. Only a pharmaceutical isolator , which has its own decontamination system, may be placed in an ISO Class 8 or better room without a separate anteroom. A CAI or CACI in unclassified space is treated as an SCA and limited to Category 1.

Starting Components: Sterile commercial products (sterile-to-sterile) OR non-sterile bulk active pharmaceutical ingredients (APIs) and raw excipients.

Sterilization Protocols: When using non-sterile components, the preparation must undergo validated terminal sterilization (e.g., saturated steam autoclave cycle) or sterilizing filtration using a certified sterile 0.22-micron membrane filter accompanied by post-filtration bubble-point integrity testing.

Beyond-Use Dating Framework for Category 2:

Category 2 BUDs are governed by four distinct parameters: starting material sterility, sterilization method, sterility release testing status, and storage temperature.

Preparation Methodology Sterility Testing (USP <71>) Controlled Room Temp (20°C to 25°C) Refrigerated (2°C to 8°C) Frozen (-25°C to -10°C)

  • Aseptically prepared; sterile starting materials only Not Performed 4 days 10 days 45 days
  • Aseptically prepared; non-sterile starting materials Not Performed 1 day 4 days 45 days
  • Terminally sterilized (autoclaved); any starting components Not Performed 14 days 28 days 45 days
  • Aseptically prepared; sterility test passed Performed & Passed (USP <71>) 30 days 45 days 60 days
  • Terminally sterilized; sterility test passed Performed & Passed (USP <71>) 45 days 60 days 90 days
  • Category 3 Compounded Sterile Preparations

Category 3 represents advanced, highly regulated compounding designed for facilities requiring extended beyond-use dating—up to 60, 90, or 120 days —to support batch manufacturing, regional health-system distribution networks, or home infusion therapies.

Warning

Category 3 Regulatory Rigor: Category 3 compounding is NOT merely Category 2 compounding with an extended date label. It imposes strict analytical, engineering, garbing, and personnel testing mandates. Operating under Category 3 requires an operational commitment and quality infrastructure comparable to pharmaceutical manufacturing.

Mandatory Prerequisites for Category 3 Compounding:

Cleanroom Suite Mandate: Category 3 CSPs must be compounded in a cleanroom suite, or in a pharmaceutical isolator placed in an ISO Class 8 or better room. They can never be made in an unclassified Segregated Compounding Area (SCA).

Garbing: In the buffer room where Category 3 CSPs are made, no skin may be exposed , so the face and neck are covered. All low-lint outer garb must be sterile , including sterile sleeves over RABS gauntlets. Disposable garb is not reused, and laundered garb must be relaundered and resterilized with a validated cycle before reuse. Goggles and respirators do not have to be sterile, but the SOPs must describe how they are disinfected. These rules apply in that buffer room at all times, even on days when no Category 3 CSP is made.

Personnel Competency Cadence: Garbing competency (visual observation plus gloved fingertip and thumb sampling) and aseptic manipulation competency (media fill, gloved fingertip sampling, and surface sampling of the direct compounding area) are repeated at least every 3 months , instead of every 6 months for Categories 1 and 2.

Environmental Monitoring Frequency:

Viable air sampling of all classified areas within 30 days before Category 3 compounding starts and at least monthly afterward, compared with every 6 months for Categories 1 and 2.

Surface sampling of all classified areas and pass-through chambers at least weekly , and before any Category 3 BUD is assigned.

Surface sampling inside the PEC at the end of each batch , before cleaning and disinfection. For a self-enclosed robotic device, it is done at least daily at the end of operations.

Sporicidal Disinfection: A sporicidal disinfectant is applied at least weekly , compared with monthly for Categories 1 and 2.

Stability Data: The BUD must be supported by stability data from a stability-indicating analytical method , meaning one that separates the drug from its degradants and impurities. The data may come from a published or unpublished study, as long as the formulation (ingredients of identical grade and procedure) and the container-closure materials are exactly the same. The study does not need to be repeated for each batch.

Release Sterility and Endotoxin Testing: Every Category 3 batch is sterility tested per USP <71>, or by a validated alternative method per USP <1223>. Any CSP requiring sterility testing is capped at 250 final yield units per batch. Injectable Category 3 CSPs made from any nonsterile component must also pass bacterial endotoxin testing per USP <85>.

Maximum Category 3 BUD Ceilings:

Aseptically prepared: 60 days controlled room temp, 90 days refrigerated, 120 days frozen.

Terminally sterilized: 90 days controlled room temp, 120 days refrigerated, 180 days frozen.

Note

USP's FAQ lists container closure integrity and particulate matter among the factors to weigh when assigning any BUD conservatively. The chapter also requires closure integrity evaluation (USP <1207>) for multiple-dose CSPs. It does not, however, list a separate container closure integrity test as a Category 3 release requirement.

Master Comparison Table: Categories 1, 2, and 3 CSPs

Operational Quality Parameter Category 1 CSP Category 2 CSP Category 3 CSP

PEC Engineering Control ISO Class 5 (LAFW, BSC, CAI, CACI) ISO Class 5 (LAFW, BSC, CAI, CACI) ISO Class 5 PEC in ISO 7 buffer room, or pharmaceutical isolator in ISO 8 room

SEC Environmental Standard Unclassified SCA or Cleanroom Suite Certified Cleanroom Suite (ISO 7 Buffer + ISO 7/8 Ante) Certified Cleanroom Suite (ISO 7 Buffer + ISO 7/8 Ante)

Starting Materials Allowed Sterile or Non-sterile (if sterilized) Sterile or Non-sterile Sterile or Non-sterile

Release Sterility Testing (USP <71>) Not required Optional (extends BUD if passed) Mandatory for every batch before release

Bacterial Endotoxin Testing (USP <85>) Not required Required for injectables with nonsterile components when the BUD requires sterility testing; recommended otherwise Mandatory for injectables with any nonsterile component

Stability-Indicating Data Not required (Table 12 limits) Not required (Table 13 limits) Mandatory : stability-indicating data for the exact formulation and container

  • Sporicidal Disinfectant Frequency At least monthly At least monthly At least weekly
  • Personnel Re-qualification (GFT & MFT) Every 6 months Every 6 months Every 3 months (Quarterly)
  • Viable Airborne Microbial Sampling Every 6 months Every 6 months Within 30 days before starting, then monthly

Surface Microbial Sampling Frequency At least monthly At least monthly At least weekly , plus the PEC after every batch

Operator Garbing Standard Standard minimum garb (same for SCA and cleanroom) Standard minimum garb No exposed skin ; sterile low-lint outer garb

Maximum Refrigerated BUD Ceiling 24 hours 60 days (terminally sterilized and sterility tested) 90 days (aseptic) or 120 days (terminally sterilized)

Personnel Competency and Re-Qualification Protocols

Personnel qualification represents a major pillar of sterility assurance under USP <797>. Personnel competency is assessed via two objective microbiological simulations:

Gloved Fingertip and Thumb Sampling (GFT): Evaluates garbing competency and hand hygiene. Both hands are sampled onto contact agar plates containing neutralizing agents immediately after garbing.

Initial Qualification: Compounding personnel must successfully complete three consecutive GFT evaluations with 0 Colony Forming Units (CFU) for both hands combined.

Ongoing garbing competency: The visual observation plus GFT after garbing repeats at least every 6 months for Category 1 and 2 compounders and every 3 months for Category 3. The action level is still > 0 CFU . The > 3 CFU action level (both hands combined) applies only to the GFT taken inside the PEC right after a media-fill test.

Media-Fill Testing (MFT): Simulates the most challenging compounding manipulations using sterile microbiological growth medium (e.g., Soybean-Casein Digest Medium / Tryptic Soy Broth [TSB]). Units are incubated for at least 7 days at 20°C to 25°C and at least 7 days at 30°C to 35°C, in an order the facility's SOPs specify. Any turbidity is a failure. The aseptic manipulation competency also includes a GFT inside the PEC (action level > 3 CFU) and surface sampling of the direct compounding area. Failing any one of the three fails the whole evaluation.

Operational Decision Algorithm for CSP Classification

When a sterile compounding workflow is designed, pharmacists must apply a systematic decision hierarchy:

Step 1: Physical Environment: Is the PEC situated in an unclassified Segregated Compounding Area (SCA)?

If YES: The preparation is automatically designated as Category 1 . Maximum BUD is 12 hours room temperature or 24 hours refrigerated.

If NO (it is in a certified cleanroom suite): Proceed to Step 2.

Step 2: BUD Duration Requirement: Does the required beyond-use dating exceed standard Category 2 parameters (e.g., > 10 days refrigerated for sterile-to-sterile without sterility testing, or > 45 days refrigerated with sterility testing)?

If NO: Compound under Category 2 standards.

If YES: Proceed to Step 3.

Step 3: Category 3 Prerequisite Audit: Has the facility fulfilled every Category 3 mandate?

Quarterly garbing and aseptic manipulation competency for every Category 3 compounder?

Monthly viable air sampling, weekly surface sampling, and PEC surface sampling after each batch?

Weekly sporicidal disinfection?

No exposed skin and sterile outer garb in the Category 3 buffer room at all times?

Stability-indicating data for the exact formulation and container-closure system?

Sterility testing of every batch (250 units maximum), plus endotoxin testing for injectables made from nonsterile components?

If YES to all: May compound and release as Category 3 .

If NO to any single parameter: The preparation cannot be assigned a Category 3 BUD and must be restricted to Category 2 dating.